Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Anti-amyloid beta (Aβ) monoclonal antibody (1) ·
Antidepressant (1) ·
Anxiolytic (1) ·
Dual orexin receptor antagonist (DORA) (1) ·
SNRI (1) ·
the first approved (1) ·
[[:Category:Anesthetics|Anesthetic]] (1) ·
[[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan Williams Class IB)]] (1) ·
[[:Category:Local anesthetics|Local anesthetic (amide class)]] (1)
None (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1)
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1)
None (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
Infiltration: 1-2% solution; '''4.5 mg/kg ceiling without epinephrine, 7 mg/kg with epinephrine'''. IV antiarrhythmic: 1-1.5 mg/kg bolus then infusion 1-4 mg/minute. Lidoderm patch: up to 3 patches per 12 hours (1) ·
Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.


